School of International Biodesign (SIB) erstwhile Stanford India Biodesign programme is a flagship programme of Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India being implemented since 2008. This biomedical technology innovation programme is being implemented at All India Institute of Medical Sciences (AIIMS) and Indian Institute of Technology (IIT-Delhi) in collaboration with International institutes including Stanford University, USA, Queensland University, Australia, Tottori University, Japan, Hiroshima University, Japan. Biotech Consortium India Limited (BCIL) has been authorised by DBT to manage this programme with particular references to its techno-legal matters including comprehensive Intellectual Property Management and Technology-Transfer.

The mandate of this programme is to train the next generation of medical technology innovators in India and to develop innovative medical device technologies as per unmet needs of India. The focus is on invention/innovation and early stage development of affordable and accessible medical technologies for our population. This is facilitated through Fellowship programme, which is a year-long, international, interdisciplinary, team-based, experiential hands-on training programme. BCIL with more than 27 years of experience, works very closely with stakeholders for policy formulations and brilliant medtech innovators (physicians, engineers, designers, entrepreneurs and researchers) assisting them in identifying unmet clinical needs, designing and prototyping solutions, developing business plans for implementing these technologies, facilitating start-up company formation and technology-transfers.

Services Offered by BCIL

The SIB programme has been successful in encouraging medical device innovations, promoting entrepreneurship in medical device sector by formation of startups, indigenous manufacturing of medical devices and dissemination of innovations at national and global level. Under SIB, around 100 Medtech innovators have been trained, 42 prototypes developed, 50 patents filed, 19 technologies transferred, 11 start-up companies formed and 5 devices have been commercially launched.

School of International Biodesign, Department of Biotechnology